Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)

Status:
Completed

Trial end date:
2015-04-01

Target enrollment:

Participant gender:

The main purposes of this study are to describe the pharmacodynamic effects, safety and pharmacokinetics of a single dose of sarilumab.

Phase 1

Regeneron Pharmaceuticals

Sanofi